Almirall says lebrikizumab maintains atopic dermatitis efficacy through 5 years in ADlong trial

By Public Technologies
  • Almirall outlined new clinical and real-world evidence for lebrikizumab in atopic dermatitis, with results presented at EADV 2026.
  • Data showed consistent symptom control across body regions, including face and neck involvement, supporting broader use in high-impact disease.
  • A late-breaking ADlong update to be presented at EADV reported sustained improvements in skin signs and itch with up to five years’ treatment.
  • New POSITIVE two-year findings presented at EADV indicated tildrakizumab improved overall well-being and quality of life beyond skin clearance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Almirall SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202609300100BIZWIRE_USPR_____20260929_BW500868) on September 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.